Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Saroja Pharma Industries India's EV-to-FCF or its related term are showing as below:
NSE:SAROJA'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.74 Med: -13.75 Max: -4.99
Current: -17.35
During the past 5 years, the highest EV-to-FCF of Saroja Pharma Industries India was -4.99. The lowest was -21.74. And the median was -13.75.
NSE:SAROJA's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 19.855
vs NSE:SAROJA: -17.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Saroja Pharma Industries India (NSE:SAROJA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Saroja Pharma Industries India's PE Ratio (TTM) for today is calculated as:
Saroja Pharma Industries India's share price for today is ₹40.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Saroja Pharma Industries India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹2.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Saroja Pharma Industries India EV-to-FCF Related Terms
Saroja Pharma Industries India EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saroja Pharma Industries India EV-to-FCF Chart
Saroja Pharma Industries India Annual Data
Trend
Mar21
Mar22
Mar23
Mar24
Mar25
EV-to-FCF
0.00
0.00
0.00
-5.27
-16.80
Saroja Pharma Industries India Semi-Annual Data
Mar21
Mar22
Mar23
Mar24
Mar25
EV-to-FCF
0.00
0.00
0.00
-5.27
-16.80
NSE:SAROJA vs ZTS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Saroja Pharma Industries India's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saroja Pharma Industries India EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Saroja Pharma Industries India's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Saroja Pharma Industries India's EV-to-FCF falls into.
Saroja Pharma Industries India's current Enterprise Value is ₹255.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Saroja Pharma Industries India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-14.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saroja Pharma Industries India (NSE:SAROJA) has a EV-to-FCF of -17.69 as of Aug. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Saroja Pharma Industries India and its competitors. According to the industry distribution chart, Saroja Pharma Industries India ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Saroja Pharma Industries India's EV-to-FCF too high?
Saroja Pharma Industries India's current EV-to-FCF is -17.69. Based on the distribution chart, Saroja Pharma Industries India ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Saroja Pharma Industries India has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Saroja Pharma Industries India's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Saroja Pharma Industries India ranks #999999 out of 564 companies for EV-to-FCF. This places Saroja Pharma Industries India in the lower half of its industry. The industry median EV-to-FCF is 19.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.86, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Saroja Pharma Industries India and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saroja Pharma Industries India's current EV-to-FCF is -17.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saroja Pharma Industries India stock overvalued right now?
Saroja Pharma Industries India (NSE:SAROJA) has a current EV-to-FCF of -17.69. The current EV-to-FCF is -17.69. Saroja Pharma Industries India's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Saroja Pharma Industries India (NSE:SAROJA), the current EV-to-FCF is -17.69 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Saroja Pharma Industries India Ltd is a company engaged in the pharmaceutical and healthcare sector. The company trades in pharmaceutical active pharmaceutical ingredients, pharma intermediates, chemicals, and solvents used for pharmaceutical products, including human and veterinary medicines. The company has only one reportable business segment, which is pharma chemicals, such as thionyl chloride and pharmaceutical intermediates. Geographically, it operates in India, Asia Pacific, Europe, and other regions, with the majority of its revenue generated from India.
15GF Score
Get the complete analysis for NSE:SAROJA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAROJA has been successfully added to your 
